Interleukin-17F Simoa

Interleukin 17F is a member of the IL-17 family, which includes 6 members (IL-17A, B, C, D, E, and F). IL-17F shares ~50% homology to IL-17A, is co-expressed with IL-17A, and is also produced often along with IL-17A primarily by T cell helper type 17 cells. Additionally, IL-17F can be secreted as a homodimer or a heterodimer with IL-17A. Homodimers or heterodimers of IL-17F signals through the same receptor (IL-17RA/RC), which is expressed primarily on non-hematopoietic cells. IL-17F has been correlated with all diseases that IL-17A has been implicated as a main pathogenic factor. These include inflammation due to autoimmune diseases, rheumatic diseases, certain cancers, and transplant rejection. While most studies demonstrate that IL-17A is more potent compared to IL-17F, it has become clear that the activity of IL-17F is synergistic with IL-17A in various autoimmune diseases. Clinical studies have repeatedly demonstrated that blockage of both IL-17A and IL-17F is most effective at improving disease activity and/or progression. IL-17F is believed to play a bigger role in mucosal immunity. For airway inflammation that is dominated by neutrophils, such as neutrophilic severe asthma, IL-17 concentration in airway fluids correlates with neutrophil numbers, suggesting a more pathological role for IL-17F compared to IL-17A.

Swiss-Prot Accession Number: Q96PD4